Validation of a simplified HPV genotyping assay designed for cervical screening in low-resource settings
Open Access
- 19 February 2025
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 63 (2) , e0163924
Abstract
Human papillomavirus (HPV) genotype predicts cervical cancer risk, and genotyping could help guide the management of HPV positives as part of cervical screening. An isothermal amplification HPV extended genotyping test (ScreenFire HPV RS assay) can assay up to 96 samples/controls in 1 hour plus preparation time. A novel format with pre-aliquoted reagents and an anti-contamination component (Zebra BioDome) could simplify the HPV testing process and reduce the chances of post-amplification contamination. We validated the Zebra BioDome formulation prior to its clinical use. Residual provider-collected cervical samples ( n = 450) from a population-based study in rural Nigeria were retested with ScreenFire, once using the standard assay version (liquid reagents combined onsite) and twice with Zebra BioDome. HPV results with adequate DNA ( N = 427) were analyzed channel-by-channel and using the cervical cancer risk-based hierarchy of HPV type channels (HPV16, else 18/45, else 31/33/35/52/58, else 39/51/56/59/68, else high-risk HPV negative) to evaluate Zebra BioDome repeatability and accuracy against the standard version. Zebra BioDome reduced the number of pipetting steps to run the ScreenFire HPV assay. Following amplification, the BioDome material formed a sealant layer above the reaction components. Zebra BioDome had excellent repeatability and agreement with the standard version, both at the channel-specific analysis (positive percent agreement between 88.4% [HPV39/51/56/59/68] and 100% [HPV16]; negative percent agreement between 97.8% [HPV31/33/35/52/58] and 100% [HPV39/51/56/59/68]) and hierarchical analysis (overall agreement 97.2%). The assay version utilizing Zebra BioDome performed similarly to the previously validated standard version of the ScreenFire HPV assay and is now undergoing field evaluation. This solution has the potential to reduce assay preparation time and risk of contamination, providing a simpler, low-cost, near-point-of-care HPV testing and extended genotyping solution for cervical screening in lower-resource settings. The potential application of Zebra BioDome technology to other PCR assays should be considered. IMPORTANCE: This work validates a novel pre-packed formulation for the ScreenFire human papillomavirus (HPV) assay, which has the potential to simplify the HPV testing process and to reduce the chances of post-amplification contamination, providing a simpler, low-cost, near-point-of-care HPV testing, and extended genotyping solution for cervical screening in resource-limited settings as part of the ultimate public health goal to accelerate cervical cancer prevention. This technology can also have broad applications for other DNA amplification assays beyond HPV.Keywords
All Related Versions
This publication has 14 references indexed in Scilit:
- AmpFire HPV and ScreenFire RS HPV validation trialAmerican Journal of Clinical Pathology, 2024
- A rapid HPV typing assay to support global cervical cancer screening and risk‐based management: A cross‐sectional studyInternational Journal of Cancer, 2023
- Redesign of a rapid, low‐cost HPV typing assay to support risk‐based cervical screening and managementInternational Journal of Cancer, 2022
- A study of type-specific HPV natural history and implications for contemporary cervical cancer screening programseClinicalMedicine, 2020
- Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58JNCI Cancer Spectrum, 2018
- The age‐specific prevalence of human papillomavirus and risk of cytologic abnormalities in rural Nigeria: Implications for screen‐and‐treat strategiesInternational Journal of Cancer, 2011
- Human papillomavirus and cervical cancerThe Lancet, 2007
- High load for most high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but only HPV16 load predicts the development of incident diseaseInternational Journal of Cancer, 2007
- False-Positive Results and Contamination in Nucleic Acid Amplification Assays: Suggestions for a Prevent and Destroy StrategyEuropean Journal of Clinical Microbiology & Infectious Diseases, 2004
- Comparisons of HPV DNA detection by MY09/11 PCR methodsJournal of Medical Virology, 2002